



PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER 10/801,695
	APPLICANT	Laszlo Prokai
	FILING DATE	March 17, 2004
		GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

14419 6-16-04	D.H. Malin et al., "Subcutaneous injection of an analog of neuropeptid FF prevents naloxone-precipitated morphine abstinence syndrome", Drug and Alcohol Dependence 40 (1995), pp. 37-42.
RR	A.M. Kawasaki et al., "Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10", International Journal of Peptide & Protein Research, 42, 1993, pp. 411-419
RR	Ambo et al., "ORL1 receptor affinity & Biol. activity", J. Tohoku Phar. Univ., 47, pp. 101-107 (2000), also cited as HCPLUS DN 136:217029
14419 6-18-04	L. Prokai et al., "Combinatorial Lead Optimization of a Neuropeptid FF Antagonists", J. Med. Chem., 2001, 44, pp. 1623-1626 P.P. C. Tan et al., "Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptid FF analogs", Peptides, 20 (1999) pp 1211-1217
RR	S.N. Kulkarni et al., "The use of the message-address concept in the design of potential antagonists based on dynorphin A", Chem., Structure and Biol., Proceedings of Am. Peptide Symposium, 14 th , Columbia, OH, June 18-23, 1995/96, pp. 655-656
RR	B. Capuano et al., "Synthesis and preliminary pharmacological evaluation of 4'-arylmethyl analogues of clozapine", Australian J. of Chemistry (2002). 55(9), pp. 565-576
RR	D. Proske et al., "A Y2 Receptor Mimetic Aptamer Director against Neuropeptide Y", J. Biol. Chemistry, Vol. 277, No. 13, March 29, 2002, pp. 11416-11422

EXAMINER	R/Raymond	DATE CONSIDERED	4-13-05
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.			



PTO-1449 (Modified)	ATTY. DOCKET NO. T2315-907327US02	SERIAL NUMBER 10/801,695
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
APPLICANT Laszlo Prokai		
FILING DATE March 17, 2004	GROUP ART UNIT 1624	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1449 6-16-04	D.H. Malin et al., "Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome", Drug and Alcohol Dependence, 40 (1995), pp. 37-42.
RR	A.M. Kawasaki et al., "Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10", International Journal of Peptide & Protein Research, 42, 1993, pp. 411-419
RR	Ambo et al., "ORL1 receptor affinity & Biol. activity", J. Tohoku Phar. Univ., 47, pp. 101-107 (2000), also cited as HCPLUS DN 136:217029
1449 6-16-04	L. Prokai et al., "Combinatorial Lead Optimization of a Neuropeptide FF Antagonists", J. Med. Chem., 2001, 44, pp. 1623-1626 B.P.C. Tan et al., "Modulation of naloxone-precipitated morphine withdrawal syndromes in rats by neuropeptide FF analogs", Peptides, 20 (1999) pp. 1211-1217
RR	S.N. Kulkarni et al., "The use of the message-address concept in the design of potential antagonists based on dynorphin A", Chem., Structure and Biol., Proceedings of Am. Peptide Symposium, 14 th , Columbia, OH, June 18-23, 1995/96, pp. 655-656
RR	B. Capuano et al., "Synthesis and preliminary pharmacological evaluation of 4'-arylmethyl analogues of clozapine", Australian J. of Chemistry (2002). 55(9), pp. 565-576
RR	D. Proske et al., "A Y2 Receptor Mimetic Aptamer Director against Neuropeptide Y", J. Biol. Chemistry, Vol. 277, No. 13, March 29, 2002, pp. 11416-11422

EXAMINER	R/Vayalil	DATE CONSIDERED	4-13-05
----------	-----------	-----------------	---------

EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered.
Include copy of this form with next communication to applicant.